# Market Madness: The Reverse-Split Rollercoaster! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-09-07T14:01:00.467Z Source: https://newsyai.com/edition/6f742e3d-c0c9-4c3a-be80-036e2ceb9d2a Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Market Mayhem: Reverse-Split Roulette 20.0 – Regenerative Stem-Cell Stiffies, Phage Therapy Pumpers & EV Charging Moonshots (September 7, 2026 Edition!)** Futures mixed (Dow flatter than a microcap’s post-split float, Nasdaq still riding the AI/chip wave like a horny quant on earnings day, crude oil doing its usual volatile lap dance). MVLS drama paused, but the microcap reverse-split parade marches on—yesterday’s media moonshots and bookkeeping stiffies? Yesterday’s news. Fresh meat today: three compliance desperados with real narrative juice—regenerative stem-cell play, phage therapy biotech, and EV charging tech with China vibes. Bulls chant “shrunken float + pipeline pop = rocket”; bears smell cash bonfires, serial dilution, and delisting hangovers.[[1]](https://www.tipranks.com/news/upcoming-stock-splits-this-week-september-7-to-september-11-stay-invested) ### 1) BRTX (BioRestorative Therapies, Inc.): “1-for-20 Stem-Cell Stiffy vs. Offering Limp Dick & Compliance Hangover” **Why it’s loud** 1-for-20 reverse split effective around September 7-8 for Nasdaq bid-price compliance (after a sharp drop post-$5M offering earlier this year). Regenerative medicine player focused on stem-cell therapies for disc degeneration and other orthopedic issues—tiny float, big dreams, repeated compliance fights.[[1]](https://www.tipranks.com/news/upcoming-stock-splits-this-week-september-7-to-september-11-stay-invested) **Bull case (compliance rocket + stem-cell boner)** 20x ratio + “regenerative tailwinds in booming ortho/biotech markets” = quick rip on the shrunken float. Ride any positive trial data, partnership, or sector hype wave, degens—pipeline progress or liquidity unlock = explosive percentage moves. Tiny float + real medical need could spark a degen squeeze! **Bear case (offering limp dick & dilution tsunami)** Post-offering price collapse + serial compliance chaser screams cash bonfire; execution risks on early-stage therapies, governance quirks, and microcap volatility = sub-penny graveyard after any pop. Short the fade before the next raise or trial miss! **My take, first principles (real regenerative signal vs. listing cancer)** Orthopedic demand and stem-cell potential are legitimate and growing, but repeated splits, recent heavy dilution, and pre-revenue cash burn point to short-term pop on compliance/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.30–2.80** range, **$0.90C** pipeline pump—**P$0.30** dilution fade. ### 2) PHGE (BiomX Inc.): “1-for-10 Phage Therapy Stiffy vs. Infection-Fighting Dreams & Cash Burn Nightmares” **Why it’s loud** 1-for-10 reverse split effective September 8 for Nasdaq compliance. Biotech using bacteriophage (phage) therapy to target stubborn infections—niche but potentially huge in the age of antibiotic resistance, with pipeline updates possible amid ongoing cash pressures.[[2]](https://capedge.com/stock-split-calendar) **Bull case (compliance rocket + phage boner)** 10x ratio + “phage tailwinds in exploding antimicrobial resistance markets” = quick rip on the shrunken float. Ride any positive preclinical/clinical data or Big Pharma interest wave, degens—platform validation or deal = explosive moves. Tiny float + real unmet need could fuel a squeeze! **Bear case (cash burn limp dick & dilution tsunami)** Pre-revenue biotech with chronic cash burn + compliance desperation screams execution hell; clinical risks, regulatory hurdles, and microcap volatility = sub-penny graveyard after any hype pop. Short the fade before the next offering or trial flop! **My take, first principles (real phage signal vs. listing cancer)** Antibiotic resistance is a massive, growing problem and phage tech has real scientific promise, but repeated compliance drama, cash burn, and early-stage risks point to short-term pop on news rather than fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.25–2.40** range, **$0.75C** data pump—**P$0.25** dilution fade. ### 3) UCAR (U Power Limited): “1-for-20 EV Charging Stiffy vs. China Tech Dreams & Liquidity Limbo” **Why it’s loud** 1-for-20 reverse split effective September 8 for Nasdaq compliance. EV-related tech play (battery swapping/charging infrastructure) with China exposure—niche market potential amid global EV push, but microcap volatility and past compliance issues.[[2]](https://capedge.com/stock-split-calendar) **Bull case (compliance rocket + EV boner)** 20x ratio + “EV infrastructure tailwinds in booming global electrification markets” = quick rip on the shrunken float. Ride any China policy boost, contract win, or sector rebound wave, degens—tech validation or partnership = explosive percentage moves. Tiny float + real EV need could spark a squeeze! **Bear case (China limp dick & dilution tsunami)** Compliance-driven split on a cash-hungry microcap with geopolitical/execution risks screams dilution hell; market adoption challenges and volatility = sub-penny graveyard after any pop. Short the fade before the next raise or EV hype miss! **My take, first principles (real EV signal vs. listing cancer)** EV infrastructure demand is real and scaling globally, but repeated splits, cash pressures, and microcap/China risks point to short-term pop on compliance/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.20–2.10** range, **$0.65C** EV pump—**P$0.20** dilution fade. **Tape-Side Tactics (BRTX Stem-Cell Gambles, PHGE Phage Pumpers & UCAR EV Moonshots – September 7 Edition)** - **BRTX**: **$0.30–2.80** stiffy; **$0.90C** pipeline pump, **P$0.30** dilution fade. - **PHGE**: **$0.25–2.40** stiffy; **$0.75C** data pump, **P$0.25** dilution fade. - **UCAR**: **$0.20–2.10** stiffy; **$0.65C** EV pump, **P$0.20** dilution fade. MVLS pressure paused but the reverse-split addiction still tightening the noose amid AI hype and micro-madness. Balls-deep DYOR, NFA, degens—duck the dilutions! **Sources** (for tracking every claim above): - Reverse splits & calendars: TipRanks Stock Splits Calendar, CapEdge, StockTitan, company PRs (Sep 2026 data).[[1]](https://www.tipranks.com/news/upcoming-stock-splits-this-week-september-7-to-september-11-stay-invested) - Company context & filings: SEC/6-K announcements, GlobeNewswire/PR Newswire via recent reports. - Broader microcap/premarket context & volatility: Yahoo Finance, StockTitan, company IR pages.